Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Biological Response Modifiers Advisory Committee

Executive Summary

Will meet Jan. 16-17. On the first day, Cytogen's OncoScint OV 103 for the diagnosis of primary and recurrent ovarian carcinoma will be reviewed. OncoScint is the first Cytogen product to come before an advisory committee. On Jan. 17, the committee will discuss for the second time, Cetus' Proleukin (interleukin-2) for the treatment of metastatic renal cell carcinoma. In July 1990, the committee suggested that Cetus reanalyze its efficacy data and conduct new studies ("The Pink Sheet" Aug. 6, 1990, p. 6). The company complied and supplied the results of its reanalysis to FDA in December 1990. The meeting, at the Bethesda, Md. Holiday Inn, 8120 Wisconsin Ave. will begin at 10 a.m. on the 16th and at 8:30 a.m. the following day. The committee also will meet in a closed session on Jan. 17.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts